-logo.){kind=logo}
MoonLake Immunotherapeutics (NASDAQ: MLTX)
Creating next-level therapies for inflammatory skin and joint diseases with Nanobody® science
Creating next-level therapies for inflammatory skin and joint diseases with Nanobody® science
MoonLake Immunotherapeutics (NASDAQ: MLTX)
MoonLake Immunotherapeutics AG is a Switzerland-based biotechnology company founded in 2021. It is a clinical-stage biopharmaceutical company utilizing Nanobody® technology to develop advanced therapies for immunologic diseases, particularly targeting inflammatory skin and joint diseases.
The company's mission is to create next-level medicines leveraging revolutionary Nanobody® science. MoonLake Immunotherapeutics AG focuses on addressing unmet medical needs in the field of inflammatory diseases, aiming to bring innovative and effective treatment options to patients.
Recently, the company announced a significant milestone with a $400.00M Post-IPO Equity investment on 28 June 2023. This injection of funds is expected to support the advancement of its clinical programs and the further development of its proprietary platform technology.
MoonLake Immunotherapeutics AG's commitment to leveraging cutting-edge technology and targeting high-demand therapeutic areas positions it as a promising player in the biotechnology industry, particularly in the treatment of inflammatory skin and joint diseases.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $400.00M | - | 28 Jun 2023 | |
| Post-IPO Equity | $115.00M | 9 |
|
06 Apr 2022 |
| Series A | Unknown | 1 | Biotechnology Value Fund | 11 May 2021 |
No recent news or press coverage available for MoonLake Immunotherapeutics (NASDAQ: MLTX).
We care about your data, and we'd love to use cookies make your experience better.